HOME > BUSINESS
BUSINESS
- Astellas Ventures into Medical Device Arena with Iota Deal
September 17, 2019
- Japan Still in Transition towards Comprehensive Genomic Profiling, Health Coverage Would Expand: Chugai Official
September 17, 2019
- Eisai, Biogen Drop PIII Studies for Elenbecestat
September 17, 2019
- ViiV Files Anti-HIV Drug Combo Dovato in Japan
September 17, 2019
- Promotion Push Continues for Daiichi Sankyo’s Pain Drug Tarlige in July: Impact Track
September 13, 2019
- Takeda, PwC to Develop App for Crohn’s Disease
September 13, 2019
- MSD Files HIV-1 Drug Doravirine in Japan
September 13, 2019
- Chugai’s Satralizumab Hits Primary Target in PIII Study
September 13, 2019
- IT Startup Activaid Offers Clinical Trial Matching Service for IBD Patients through App
September 12, 2019
- Opdivo Showed 5-Year Survival Rates of 13.4% in 2nd-Line NSCLC in PIII Studies
September 12, 2019
- Fujifilm Rolls Out iPS Cell-Derived Small Intestinal Cell in Japan for Use in Assessing Drug Absorption
September 12, 2019
- Full Approval in Japan Will Be 1st Goal for Collategene: AnGes Chief
September 11, 2019
- Vital-Net Carving Out New Businesses in Regenerative Medicine, Robotics
September 11, 2019
- Keytruda Filed for Esophageal Cancer in Japan
September 11, 2019
- Wakamoto Casts Off Glaucoma Hopeful on Safety Worries
September 11, 2019
- Daiichi Sankyo Presents Updated PI Data of ADCs DS-1062, U3-1402 for NSCLC
September 11, 2019
- 1st RNAi Therapy Onpattro Makes Japan Debut
September 10, 2019
- Daiichi Sankyo’s Big-Seller Hopeful DS-8201 Filed in Japan
September 10, 2019
- Japan Lung Cancer Market to Surge to 317.5 Billion Yen in 2027: Fuji Keizai
September 10, 2019
- Japan Ethical Drug Sales Zoom 7.0% in July: Crecon
September 9, 2019
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
